Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

NovaDel Pharma Licenses Nitroglycerin Lingual Spray

By Pharmaceutical Processing | September 21, 2004

NovaDel Pharma Inc has announced that it has entered into a licensing agreement with Par Pharmaceutical to market its nitroglycerin lingual spray.

In June 2004, NovaDel filed a New Drug Application with the US FDA seeking marketing approval for its aerosol lingual spray version of nitroglycerin under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. Under PDUFA guidelines, the company said a 10-month review period is customary.

If approved as submitted, the product would be indicated for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. The product is delivered via a metered dose dispenser designed to ensure accurate dose delivery. This will enable patients to conveniently self-administer the product.”Par Pharmaceutical is a very successful marketer of pharmaceutical products and we are delighted to have them on board as a partner for our first product submitted for approval,” said Gary A. Shangold, MD, NovaDel’s President & CEO.

Under the terms of the agreement, Par has exclusive rights to market, sell and distribute nitroglycerin lingual spray in the US and Canada. NovaDel is responsible for obtaining regulatory approval for the product and for supplying the product to Par. NovaDel will receive milestone payments and double-digit royalties on sales of the product.

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic pharmaceuticals through its principal subsidiary, Par Pharmaceutical, Inc. and its recently acquired subsidiary, Kali Laboratories, Inc. Par currently manufactures, markets or licenses more than 80 prescription drugs.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE